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Symptom Clusters in Adults with Chronic Atrial Fibrillation
Abstract
BACKGROUND: Symptom clusters have not previously been explored among individuals with atrial
fibrillation of any type.
OBJECTIVE: The purpose of this study is to determine the number of symptom clusters present among
adults with chronic atrial fibrillation and to explore sociodemographic and clinical factors potentially
associated with cluster membership.
METHODS: This was a cross-sectional secondary data analysis of 335 Australian community-dwelling adults
with chronic (recurrent paroxysmal, persistent, or permanent) atrial fibrillation. We used self-reported
symptoms and agglomerative hierarchical cluster analysis to determine the number and content of symptom
clusters present.
RESULTS: There were slightly more male (52%) than female participants, with a mean (SD) age of 72
(11.25) years. Three symptom clusters were evident, including a vagal cluster (nausea and diaphoresis), a tired
cluster (fatigue/lethargy, weakness, syncope/dizziness, and dyspnea/breathlessness), and a heart cluster
(chest pain/discomfort and palpitations/fluttering). We compared patient characteristics among those with
all the symptoms in the cluster, those with some of the symptoms in the cluster, and those with none of the
symptoms in the cluster. The only statistically significant differences were in age, gender, and the use of
antiarrhythmic medications for the heart cluster. Women were more likely to have the heart symptom cluster
than men were. Individuals with all of the symptoms in the heart cluster were younger (69.6 vs 73.7 years; P =
.029) than those with none of the symptoms in the heart cluster and were more likely to be on antiarrhythmic
medications.
CONCLUSION: Three unique atrial fibrillation symptom clusters were identified in this study population.
Keywords
Adult, Aged, Aged, 80 and over, Atrial Fibrillation, Australia, Chronic Disease, Cluster Analysis, Cross-
Sectional Studies, Female, Humans, Male, Middle Aged, Socioeconomic Factors, Symptom Assessment
Disciplines
Cardiology | Cardiovascular Diseases | Circulatory and Respiratory Physiology | Medicine and Health
Sciences | Nursing | Preventive Medicine
This journal article is available at ScholarlyCommons: https://repository.upenn.edu/nrs/129
Symptom Clusters in Adults with Chronic Atrial Fibrillation
Megan Streur, RN, MN [Doctoral Student],
University of Pennsylvania, School of Nursing, Philadelphia PA
Sarah J Ratcliffe, PhD [Associate Professor],
University of Pennsylvania, Perelman School of Medicine, Division of Biostatistics, Philadelphia 
PA
Jocasta Ball, PhD [Post-Doctoral Research Fellow],
Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne Australia
Simon Stewart, RN, PhD [Professor], and
Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne Australia
Barbara Riegel, RN, PhD [Professor]
University of Pennsylvania, School of Nursing, Philadelphia PA
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia, with an estimated global 
prevalence of 2.8%.1 AF affects more than 3 million individuals in the United States (US) 
alone.2 Emergency department visits and hospitalizations for AF are costly and rising both 
in the US and globally. In the US, emergency department visits for AF increased by 88% 
between 1993 and 2004.3 Approximately 64% of those seen in US emergency departments 
for AF are subsequently hospitalized.3 The direct cost of AF in the US is nearly 7 billion 
dollars annually, which is primarily attributable to hospitalizations.4 Globally, the proportion 
of healthcare spending attributable to the direct costs of AF ranges from 0.28 to 1.01%.1 By 
2020 the cost of AF-related hospitalizations is predicted to increase by 55% compared to 
2010.5 Symptoms are a main predictor of hospitalizations among individuals with AF.6
Symptoms are an important but under-researched aspect of AF. A wide spectrum of 
symptom experiences occur among AF patients, with some experiencing multiple, severe 
symptoms and others experiencing no, few, or vague symptoms.7,8 The goals of AF 
management are to prevent severe complications associated with AF and reduce or eliminate 
symptoms. There are three primary strategies to achieve these goals: prevention of 
thromboembolism, heart rate control, and restoration of sinus rhythm.8 Preventing 
thromboembolism and rate-control are goals regardless of symptom status. AF symptoms, 
which negatively impact functional status and quality of life,9,10 are a primary consideration 
when determining whether to attempt restoration of sinus rhythm for longer-term 
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management of recurrent paroxysmal or persistent AF.8 Unfortunately, little is understood 
regarding AF symptom variability and the mechanisms of AF symptoms,11 which may 
hamper our ability to make effective treatment decisions.
While the frequency of individual AF symptoms has been described,7 it is likely that AF 
symptoms co-occur as symptom clusters; groups of two or more related and co-occurring 
symptoms.12,13 Symptom clusters occur as the result of a shared etiology, a shared 
covariance, or a shared effect on outcomes.12-15 Symptom clusters could help explain the 
variability of AF symptoms experienced and may be associated with treatment outcomes. 
Furthermore, AF-specific symptom clusters may be associated with underlying physiologic 
processes related to clinical variables, the sub-type of AF, or the etiology of AF. 
Understanding the physiology underlying symptom clusters may assist clinicians to better 
individualize treatment. If associations between symptom clusters and outcomes exist, 
providers could use symptom cluster assessment as a method of risk stratification. Thus, the 
purpose of this study was to determine the number of symptom clusters present among 
adults with chronic AF and to explore sociodemographic and clinical factors potentially 
associated with cluster membership.
Methods
This study was a cross-sectional secondary data analysis of data from a randomized 
controlled pragmatic clinical trial conducted in Australia between 2010 and 2014; the 
Standard versus Atrial Fibrillation spEcific managemenT strategY (SAFETY) Trial.16 
Applicable ethics board approvals were obtained as required for the original trial16 and 
through the University of Pennsylvania Institutional Review Board for this secondary data 
analysis. The methods and results of the trial have been reported previously.16,17 Methods 
are summarized briefly here:
A total of 335 individuals were included in the SAFETY Trial. Participants were eligible if 
they had a diagnosis of chronic AF, lived independently within the community following 
their index hospital admission (within a radius of 40km), and provided informed consent. 
Chronic AF was defined as recurrent paroxysmal, persistent, or permanent AF. Exclusion 
criteria included a primary diagnosis of valvular heart disease, a scheduled catheter ablation 
procedure, a preexisting diagnosis of heart failure (all patients were subject to 
echocardiography to exclude this diagnosis), transient AF (i.e. AF associated with acute 
myocardial infarction, pericarditis, recent cardiac surgery, sepsis, or excessive alcohol), or a 
terminal disorder or malignant disease that required palliative care.17 All participants in the 
original cohort were included in this cross-sectional secondary data analysis.
Measurement of Variables
Atrial Fibrillation Symptoms—Symptoms were measured using an AF profiling tool 
developed specifically for the SAFETY Trial. For this cluster analysis we used self-reported 
symptoms collected during the index hospitalization (Appendix 1). Each symptom was 
reported on a binary (yes/no) scale. Participants were instructed to report all symptoms 
previously or currently experienced in association with AF. Six common symptoms of AF 
were measured: dyspnea/breathlessness, syncope/dizziness, fatigue/lethargy, palpitations/
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fluttering, chest pain/discomfort, and weakness. Participants could report other symptoms 
via free-text response. Nausea and diaphoresis were commonly reported using the other 
option, and were therefore included in this analysis. Participants also reported if they did not 
experience symptoms when in AF, which was recorded as a binary yes/no response.
Clinical and Demographic Variables—All participants were comprehensively profiled 
upon enrollment in the study. All clinical and demographic variables used for this analysis 
were obtained during the baseline assessment. Variables were collected by trained study 
personnel via medical record review and patient self-report.
Statistical Analysis
All data analysis was conducted in SAS version 9.4 (Cary, North Carolina). Descriptive 
statistics were used to describe the data. Symptom clusters were identified with 
agglomerative hierarchical cluster analysis, because of our goal to create mutually exclusive 
groups of symptoms.14,18,19 Cluster analysis maximizes both the homogeneity within 
clusters and the heterogeneity between clusters.18,19 We used Ward's method with Euclidean 
distance as the dissimilarity measure.18,20 The ideal number of clusters was determined 
using a combination of dendrograms, pseudo F, and pseudo T.18,21 Additionally, we 
compared the results of the cluster analysis with exploratory factor analysis to validate our 
findings.
After identifying symptom clusters, we compared characteristics of individuals with each 
cluster to those without the cluster in order to understand the potential factors associated 
with cluster membership. To do this, we divided participants into three groups for each 
symptom cluster: those with all the symptoms in the cluster, those with some of the 
symptoms in the cluster (one or more, but not all, of the symptoms), and those with none of 
the symptoms in the cluster. Next, we used Fisher's exact test, chi-square test, and Kruskal-
Wallis one-way analysis of variance to determine the statistical significance of 13 factors to 
determine if these factors were associated with symptom cluster membership. We used a 
broad range of demographic and clinical characteristics, specifically age, gender, ethnicity, 
body mass index (BMI), Charlson Comorbidity Index,22 cardiovascular comorbidities, and 
cardiac medications. We considered these factors as potentially associated with cluster 
membership based on the results of prior research (e.g. the influence of age and gender), due 
to similarity of symptom profiles with selected comorbidities,8,11 and because of our 
assumption that certain medications may contribute to certain symptoms (e.g. beta-blockers 
and fatigue). Statistical significance was determined using the predetermined value of 
p<0.05.
Results
Sample Characteristics
The mean age of participants was 72 (±11.25), with a range of 40 to 93 years (Table 1). 
Participants were predominantly European/Caucasian (96%), and there were slightly more 
male participants (52%) than female. The majority considered themselves symptomatic 
(83%), with only 17% (n=57) reporting themselves as asymptomatic. Dyspnea/
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breathlessness was the most common symptom, affecting 56% of participants despite the 
absence of underlying heart failure.
Symptom Clusters
The dendrogram, pseudo-F and pseudo-T indicated that a three cluster solution was the 
optimal solution (Figure 1). We labeled the symptom clusters the vagal cluster (nausea and 
diaphoresis), tired cluster (fatigue/lethargy, weakness, syncope/dizziness, and dyspnea/
breathlessness), and heart cluster (chest pain/discomfort and palpitations/fluttering). Both 
vagal cluster symptoms occurred in only 3 participants. The heart cluster was the most 
common, with all symptoms occurring in 26% (n=88) of participants. All tired cluster 
symptoms were present in 14% (n=47) of participants (Table 2). Over half with the tired 
cluster (n=24) also experienced the heart cluster (Table 3).
Characteristics of Symptom Cluster Groups
There were no statistically significant differences in patient characteristics for the vagal or 
tired cluster. In the heart cluster, statistically significant differences were found in age, 
gender, AF sub-type, and use of anti-arrhythmic medications (Table 4). The mean age 
progressively declined for individuals with none (73.7 years, n=118) versus some (71 years, 
n=129) versus all (69.6 years, n=88) of the heart cluster symptoms. Participants with all the 
heart cluster symptoms were 4 years younger on average than individuals with none of the 
heart cluster symptoms (69.6 versus 73.7 years, p=0.029). Women were significantly more 
likely to have the heart cluster than men (p=0.0015), with 20% of men (n=35) and 33% of 
women (n=53) having both of the heart cluster symptoms. Heart cluster membership varied 
by AF sub-type (p=0.042). Among participants with permanent AF, 55% had none, 30% had 
some, and 15% had all of the heart cluster symptoms. In contrast, 27% of participants with 
persistent and 33% with paroxysmal AF had all of the heart cluster symptoms. In 
comparison, 18% of individuals with permanent AF had all the tired cluster symptoms, 
compared to 14% with persistent and 11% with paroxysmal AF, although not statistically 
significant. Participants with the heart cluster were more likely to take anti-arrhythmic 
medication as part of rhythm-control therapy than individuals without the heart cluster 
(p=0.002). Among participants with both heart cluster symptoms, 40% were on anti-
arrhythmics, compared to 34% for participants with one of the heart symptoms and 19% for 
participants with none of the heart symptoms. Comparatively, only 26% of participants with 
all the tired cluster symptoms were on anti-arrhythmics. Interestingly, we did not find a 
statistically significant relationship between the tired cluster and use of rate-control 
medications, even though rate-control medications have side-effect profiles similar to tired 
cluster symptoms.
Discussion
This is the first study to establish the presence of AF symptom clusters in individuals with 
chronic forms of AF. We identified three distinct clusters; a vagal cluster (nausea and 
diaphoresis), tired cluster (fatigue, weakness, syncope/dizziness, and dyspnea), and heart 
cluster (palpitations and chest pain). These clusters are unique compared to symptom 
clusters identified among other cardiovascular patient populations (Table 5).23-25 The AF 
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cluster that shares the most similarities with other cardiovascular clusters is the tired cluster, 
which shares some symptoms with heart failure physical symptom clusters. However, it is 
important to note that patients with heart failure were specifically excluded from this study 
cohort. Further, the AF tired cluster is unique because dizziness/syncope is included in our 
cluster. AF patients may have disease-specific mechanisms for dizziness/syncope, such as 
tachycardia, bradycardia or post-conversion pause, which cause this symptom to cluster with 
fatigue, weakness, and dyspnea. Alternately, these symptoms are potentially 
pharmacologically based given the fine line between benefit and risk of adverse events in 
those being treated for AF.17
The vagal cluster was quite rare (n=3) in our sample. However, the fact that symptoms 
associated with vasovagal response cluster together is interesting due to the well-recognized 
occurrence of vagally-mediated AF.8,26. It is interesting to note that syncope/dizziness were 
measured as a single item in this study and clustered with the tired symptoms, rather than the 
vagal cluster. Future studies of AF symptom clusters should measure dizziness and syncope 
as distinct symptoms to determine whether one or the other may cluster differently if 
measured independently.
The tired cluster might be considered vague or non-specific11 and therefore not easily 
attributable to AF. However, dyspnea was the most frequently reported AF symptom in our 
sample (56%), followed closely by fatigue (50%), which occurred at the same frequency as 
palpitations (50%). These findings are in contrast to the large study by Levy et al.7 which 
found palpitations were the most common symptom of AF (54%), followed by dyspnea 
(44%) and fatigue (14%). The Levy7 study examined outpatients whereas our symptom data 
are from index hospital admissions, which may explain the difference in reported symptoms. 
AF results in loss of atrio-ventricular synchrony and often in tachycardia and/or bradycardia, 
which can adversely affect hemodynamic status through impaired diastolic filling and 
impaired left ventricular systolic function.11 Hemodynamic changes associated with AF are 
a plausible mechanism for the clustering of fatigue, weakness, dyspnea, and syncope/
dizziness.
The heart cluster consists of the symptoms that may be the most readily attributed to AF, 
palpitations and chest pain. Certain individuals may be more prone to perceive sensations in 
the chest due to differences in afferent neural stimulation or central nervous system 
functioning.11,27 A study of heart transplant patients showed that despite cardiac denervation 
one-third of participants could still perceive their heartbeat, suggesting the perception of 
palpitations is unrelated to cardiac mechanoreceptors.28 Similarly, chest pain often occurs 
during AF despite the absence of acute coronary syndrome.29 Numerous studies reveal that 
neuropsychiatric variables influence the perception of AF symptoms,30-32 and palpitations in 
particular.33,34 Taken together, these findings support the idea that a mechanism outside the 
myocardium is responsible for the heart cluster symptoms. Further research is needed to 
elucidate the precise mechanisms of these symptoms. Interestingly, the heart cluster was the 
only cluster with significant differences in patient characteristics between those with versus 
without the cluster.
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Our results indicate that membership in the heart symptom cluster is associated with 
younger age, female gender, AF sub-type, and anti-arrhythmic use. Gender-based 
differences in the SAFETY cohort have been described previously: women in the cohort 
were older, more likely to experience symptomatic AF (especially fatigue, palpitations, and 
weakness), and presented with a unique clinical profile characterized by higher BMI, less 
coronary artery disease/revascularization, and more depression.35 Our study furthers these 
findings by revealing that symptom cluster membership also varies by gender. Previous 
reports indicate younger age and female gender are associated with an increased frequency 
and severity AF symptoms.31,36 However, Sears et al.32 found that age and gender were not 
significantly associated with the number of AF symptoms reported. Our results indicate that 
age and gender are indeed non-modifiable characteristics that influence certain aspects of 
symptom perception, specifically symptom clustering. While age and gender may not 
influence the number of symptoms reported, these characteristics do influence other aspects 
of symptom perception such as the type of symptoms experienced, and their perceived 
frequency and severity.
Gender differences in the SAFETY Trial may have contributed to the greater number of 
women who experienced the heart cluster. Depression was more common in women 
(p=0.017)35 and may be an important factor effecting symptom perception. Higher levels of 
negative emotions are associated with a greater number of AF symptoms, influencing the 
number of symptoms experienced more than objectively measured episodes of AF.37 
Similarly, increased severity of depression and anxiety are associated with increased AF 
symptom severity (p<0.001).31 Palpitations were significantly more common among the 
women in our study, and are known to be influenced by neuropsychiatric variables.34 It is 
plausible that differences in neuropsychiatric variables influenced the number of men versus 
women that experienced the heart cluster. BMI also varied by gender in our study. Elevated 
BMI is a well-documented risk factor for AF development.38,39 It is possible that BMI may 
also influence heart cluster membership via altered cardiac interoception,40 or as the result 
of perceived differences in symptom burden and severity.41
Heart cluster membership varied based on sub-type of AF. The results are difficult to 
interpret for participants with paroxysmal AF due to small numbers (n=9). However, our 
results indicate that permanent AF has a unique symptom presentation. Individuals with 
permanent AF were least likely to have all of the symptoms in the heart cluster. In contrast, 
these individuals were most likely to have all the tired cluster symptoms. These differences 
in symptom profile are important factors to consider in terms of clinical decision making 
related to symptom-management. Unfortunately, symptom-management options are limited 
for individuals with permanent AF: Guidelines recommend against rhythm-control, and 
therefore symptoms are primarily managed through rate-control.8 Alternative therapies, such 
as yoga and biofeedback, can reduce AF symptoms and may be the most beneficial in 
individuals with permanent AF, but these methods are understudied in this population.42,43
It is possible the large proportion of participants in the SAFETY cohort with persistent AF 
(87.5%) influenced the association between the heart cluster and anti-arrhythmic 
medication. However, the proportion of individuals with persistent AF was high both among 
individuals with all the heart cluster symptoms (90.9%) and all the tired cluster symptoms 
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(85.1%), yet a statistically significance association with anti-arrhythmics was only found in 
the heart cluster. Another possible explanation is that patients and/or providers are more 
likely to consider palpitations and chest pain as symptoms of AF, or as more severe 
symptoms of AF, compared to the vague symptoms in the tired cluster, subsequently 
resulting in selection of a rhythm-control strategy. In fact, prior research indicates patients 
often erroneously attribute AF symptoms such as dyspnea and fatigue to ageing, 
deconditioning, or poor sleep, and that these erroneous attributions result in treatment-
seeking delay prior to AF diagnosis.44-46 Further research is warranted to explore whether 
symptom attribution influences treatment decisions post-diagnosis among individuals with 
chronic forms of AF.
Limitations
This study has several limitations. First, we used symptom data collected with a survey that 
was not validated psychometrically, which could influence the cluster solution. Second, high 
levels of cognitive impairment (approximately two-thirds of participants) have been reported 
for this cohort, which likely influenced the ability of participants to recall and accurately 
report symptoms.47 However, the SAFETY cohort typifies patients with AF (minus 
individuals with concurrent heart failure), so we consider this an acceptable limitation for 
this study. Third, our findings are based on self-reported symptoms which were not 
correlated objectively with heart rhythm monitoring. Fourth, the symptoms reported in this 
study may not represent all possible symptoms of AF (e.g. emotional and cognitive 
symptoms),48,49 and as a result important clusters or components of clusters may be missing 
from this report. While we recognize the limitations of our study, we consider this work an 
important first step towards understanding symptom clusters and factors associated with 
cluster membership among adults with chronic AF.
Conclusions
We identified three symptom clusters among adults with chronic AF, demonstrating that AF 
symptoms do not always occur in isolation. Cluster membership is associated with two non-
modifiable patient characteristics; age and gender. We also demonstrated that the 
combination of chest pain and palpitations is more likely to be associated with clinical 
factors including AF sub-type and the use of anti-arrhythmic medications. Additional studies 
are warranted to replicate these findings and explore the impact of symptom clusters on 
patient treatment and outcomes.
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Figure 1. 
Dendrogram of atrial fibrillation symptom clusters. All symptoms were self-reported at 
baseline
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Table 1
Baseline Characteristics and Symptoms of the SAFETY Trial Cohort
All (N=335) Female (N=161, 48%) Male (N=174, 52%)
Sociodemographic Profile
Age (years)# 72 (±11.3) 74 (±10.3) 69 (±11.6)
Ethnicity
    European/Caucasian 323 (96.4%) 156 (96.9%) 167 (96.0%)
    Aboriginal/Torres Strait Islander 4 (1.2%) 1 (0.6%) 3 (1.7%)
    Asian 5 (1.5%) 3 (1.9%) 2 (1.2%)
    Middle Eastern 3 (0.9%) 1 (0.6%) 2 (1.2%)
Living Alone# 132 (39.4%) 82 (50.9%) 50 (28.7%)
Clinical Profile
AF Sub-Type
    Recurrent Paroxysmal 9 (2.7%) 4 (2.5%) 5 (2.9%)
    Persistent 293 (87.5%) 140 (87.0%) 153 (87.9%)
    Permanent 33 (9.9%) 17 (10.6%) 16 (9.2%)
Body Mass Index* 29.6 (±6.7) 30.5 (±7.9) 28.8 (±5.3)
Charlson Comorbidity Index 4.9 (±2.6) 5.1 (±2.4) 4.7 (±2.7)
Hypertension 240 (71.6%) 123 (76.4%) 117 (67.2%)
Coronary Artery Disease* 112 (33.4%) 40 (24.8%) 72 (41.4%)
Valve disease 12 (3.6%) 7 (4.4%) 5 (2.9%)
History of Cardiac Revascularization Surgery# 68 (20.3%) 18 (11.2%) 50 (28.7%)
Beta Blocker 165 (49.3%) 77 (47.8%) 88 (50.6%)
Calcium Channel Blocker 74 (22.1%) 39 (24.2%) 35 (20.1%)
Digoxin 117 (34.9%) 64 (39.8%) 53 (30.5%)
Anti-Arrhythmic 101 (30.2%) 51 (31.7%) 50 (28.7%)
Symptom Profile
Asymptomatic (self-reported) 57 (17.0%) 21 (13.0%) 36 (20.7%)
Dyspnea/Breathlessness 186 (55.5%) 93 (57.8%) 93 (53.5%)
Fatigue/Lethargy* 168 (50.2%) 91 (56.5%) 77 (44.3%)
Palpitations/Fluttering# 169 (50.5%) 102 (63.4%) 67 (38.5%)
Weakness* 122 (36.4%) 70 (43.5%) 52 (29.9%)
Chest Pain/Discomfort 136 (40.6%) 70 (43.5%) 66 (37.9%)
Syncope/Dizziness 119 (35.5%) 65 (40.4%) 54 (31.0%)
Nausea 21 (6.3%) 12 (7.5%) 9 (5.2%)
Diaphoresis 15 (4.5%) 8 (5.0%) 7 (4.0%)
Data are mean (± standard deviation) or number of patients (%). Characteristics that were significantly different between females and males are 
marked with an asterisk (*) for p<0.05, and with a pound sign (#) for p<0.001
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Table 2
Symptom Cluster Membership
Cluster Membership
Vagal Cluster (diaphoresis and nausea) N (%)
    None of the symptoms 302 (90%)
    Some of the symptoms 30 (9%)
    All of the symptoms 3 (1%)
Tired Cluster (weakness, fatigue, syncope/dizziness, dyspnea)
    None of the symptoms 95 (28%)
    Some of the symptoms 193 (58%)
    All of the symptoms 47 (14%)
Heart Cluster (chest pain and palpitations)
    None of the symptoms 118 (35%)
    Some of the symptoms 129 (39%)
    All of the symptoms 88 (26%)
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Table 3
Cluster Co-occurrence within the SAFETY Trial Cohort
Cluster Combinations
Vagal Heart Tired
Vagal 3 (0.9%) 2 (0.6%) 2 (0.6%)
Heart 88 (26%) 24 (7%)
Tired 47 (14%)
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Table 4
Comparison of Heart Cluster Groups
Characteristic None of the symptoms 
N=118
Some of the symptoms 
N=129
All of the symptoms N=88 p-value
Gender 0.002
    Male (%) 76 (64.4%) 63 (48.8%) 35 (39.8%)
    Female (%) 42 (35.6%) 66 (51.2%) 53 (60.2%)
Age (years) 73.7 (±10.7) 71 (±11.6) 69.6 (±11.1) 0.029
European/Caucasian Ethnicity (%) 115 (97.5%) 124 (96.1%) 84 (95.5%) 0.759
AF Sub-Type 0.042
    Recurrent Paroxysmal 5 (4.2%) 1 (0.8%) 3 (3.4%)
    Persistent 95 (80.5%) 118 (91.5%) 80 (90.9%)
    Permanent 18 (15.3%) 10 (7.8%) 5 (5.7%)
Body Mass Index 29.9 (±7.6) 29.9 (±6.5) 28.8 (±5.4) 0.710
Charlson Comorbidity Index 5.2 (±2.4) 4.8 (±2.6) 4.5 (±2.6) 0.108
Hypertension (%) 87 (73.7%) 95 (73.6%) 58 (65.9%) 0.381
Coronary Artery Disease (%) 49 (41.5%) 37 (28.7%) 26 (29.6%) 0.068
Valve Disease (%) 6 (5.1%) 6 (4.7%) 0 (0%) 0.079
Cardiac Surgery (%) 26 (22%) 23 (17.8%) 19 (21.6%) 0.672
Beta Blocker (%) 66 (55.9%) 57 (44.2%) 42 (47.7%) 0.173
Calcium Channel Blocker (%) 31 (26.3%) 26 (20.2%) 17 (19.3%) 0.392
Digoxin (%) 37 (31.4%) 49 (38%) 31 (35.2%) 0.550
Anti-Arrhythmic (%) 22 (18.6%) 44 (34.1%) 35 (39.8%) 0.002
Statistically significant differences (p±0.05) are shown in bold. Data are mean (± standard deviation) or number of patients (%).
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Table 5
Cardiovascular Symptom Clusters
Symptom Cluster
Acute Coronary 
Syndrome 
(ACS) 1
Classic ACS Cluster 
(chest pain)
Pain Cluster (arm, back, 
shoulder, neck, throat, and 
jaw pain)
Stress Cluster (shortness 
of breath, sweating, 
nausea, indigestion, 
dread, and anxiety)
Diffuse Cluster (multiple 
symptoms present but with 
low representation of any 
particular symptom)
Heart Failure 2 Physical Cluster (dyspnea, fatigue/increase need to rest, 
fatigue/low energy, and sleep disturbances)
Emotional/Cognitive Cluster (worrying, feeling depressed, 
and cognitive problems)
Heart Failure 3 Physical Capacity Cluster (dyspnea, difficulty walking or 
climbing, fatigue/increased need to rest, fatigue/low 
energy, and sleep difficulties)
Emotional/Cognitive Cluster (worrying, feeling depressed, 
and cognitive problems)
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